Oncometabolitic control of tumor growth and epileptogenesis in IDH mutated gliomas: D2HG signaling mechanism.

Project description

Metabolic control of tumour growth and epileptogenesis: the case of gliomas

Gliomas may present with mutations in the isocitrate dehydrogenase (IDH) gene, which lead to the overproduction of the oncometabolite D-2-hydroxyglutarate (D2HG). D2HG is thought to participate in both epileptogenic and oncologic processes, modulating the excitatory neurotransmitter glutamate. The scope of the EU-funded GliomaSignals project is to investigate the role of D2HG in the neurobiology of gliomas and elucidate the mechanism by which it modulates, via its effects on glutamatergic signalling, tumour growth and epilepsy processes. The project's results are expected to shed light on the high epileptic activity associated with glioma tumour invasion and unveil novel targets for therapy.

Fields of science

• natural sciences › biological sciences › neurobiology
• medical and health sciences › basic medicine › neurology › epilepsy
• medical and health sciences › clinical medicine › surgery
• natural sciences › biological sciences › genetics › mutation

Programme(s)

• H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme

Topic(s)

• ERC-2019-COG - ERC Consolidator Grant

Call for proposal

ERC-2019-COG

See other projects for this call

Funding Scheme

ERC-COG - Consolidator Grant

Host institution

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

Net EU contribution

€ 1 875 135,00

Address

Rue De Tolbiac 101
75654 Paris
France

Region

Ile-de-France › Ile-de-France › Paris

Activity type

Research Organisations

Links

Other funding

€ 1 875 135,00

Beneficiaries (1)

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

Net EU contribution

€ 1 875 135,00

Address

Rue De Tolbiac 101
75654 Paris

Region

Ile-de-France › Ile-de-France › Paris

Activity type

Research Organisations

Links

Other funding

€ 1 875 135,00